Stay updated on Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial
Sign up to get notified when there's something new on the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page.

Latest updates to the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant changes, including the addition of a new study on HIV infections and the involvement of key collaborators, while extensive details about a previous trial have been removed.SummaryDifference26%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page.